Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
John F. Crowley, President and CEO of the…
“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…
CSBA Letter to Congressional Leadership on Most…
CSBA Letter to Congressional Leadership on…
The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory-based non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative…
All Letters, Testimony & Comments
  • Show All
Search
Results
April 28, 2022
The Biotechnology Innovation Organization (BIO) is the largest biotechnology trade association, representing approximately 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United…
April 27, 2022
On Wednesday, April 27th, BIO submitted comments regarding an upcoming meeting of ODAC’s Pediatric Oncology Subcommittee on PREA Waivers for Same-in-Class Drugs. In particular, the subcommittee will meet to discuss the development of a conceptual…
April 26, 2022
As a diverse set of stakeholders dedicated to building a cleaner, more resilient aviation industry, we write today to urge your committees to prioritize funding for federal programs that will help develop and scale up the sustainable aviation fuel …
April 22, 2022
As a broad coalition of aviation industry stakeholders—including passenger and cargo carriers, clean fuel producers, engine and aircraft manufacturers, labor unions, airports, business and general aviation, airline passengers, trade…
April 21, 2022
The Biotechnology Innovation Organization (BIO) welcomes the opportunity to provide comments on the proposed Rules for the Implementation of Regulations on Management of Human Genetic Resources (HGR). BIO acknowledges the efforts of the Division of…
April 19, 2022
The farmers, cooperatives, researchers, retailers, seed producers, scientists, and technology developers represented by the organizations below write to express our strong support for the inclusion of language in the Fiscal Year 2023 (FY 2023)…
April 11, 2022
On Monday, April 11th, BIO also submitted comments in response to the CDC’s recently published Clinical Practice Guideline for Prescribing Opioids. In the comments submitted, BIO primarily requested that the CDC revise its language referencing…
April 11, 2022
On Monday, April 11th, BIO submitted comments in response to the FDA’s recent draft guidance on the Development of Non-Opioid Analgesics for Acute Pain. In the comments submitted, BIO reaffirmed its commitment to working with the Agency to achieve…
April 4, 2022
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States House of Representatives Committee on Agriculture hearing entitled, “A 2022 Review of the Farm Bill: Energy- Renewable Energy…
April 1, 2022
The Biotechnology Innovation Organization (BIO) is pleased to submit these comments in response to the U.S. Environmental Protection Agency’s (EPA’s) February 28-March 1, 2022, workshop on biofuel greenhouse gas modeling.